Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

ABSTRACT:

Purpose

Clinical trials in early breast cancer have suggested that benefits of adjuvant bone-targeted treatments are restricted to women with established menopause. We developed models that mimic pre- and postmenopausal status to investigate effects of altered bone turnover on growth of disseminated breast tumor cells. Here, we report a differential antitumor effect of zoledronic acid (ZOL) in these two settings.

Experimental design

Twleve-week-old female Balb/c-nude mice with disseminated MDA-MB-231 breast tumor cells in bone underwent sham operation or ovariectomy (OVX), mimicking the pre- and postmenopausal bone microenvironment, respectively. To determine the effects of bone-targeted therapy, sham/OVX animals received saline or 100 μg/kg ZOL weekly. Tumor growth was asse

SUBMITTER: Ottewell PD 

PROVIDER: S-EPMC4040234 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature